Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

There is no abstract available for this article on the effects of percutaneous oestradiol implants on the skeletons of postmenopausal women, and thus no new findings are reported.

In this study, low-dose oral minoxidil for hair loss was associated with infrequent systemic adverse effects, and only 1.7% of patients discontinued treatment due to these effects.

This article is a letter to the editor about high-dose pulsed corticosteroid therapy combined with methotrexate for severe childhood alopecia areata and provides no new clinical results.

This study found a strong dose-related increase in the risk of intracranial meningiomas associated with high doses of cyproterone acetate, with some reduction in risk after stopping the treatment.

This study found that among patients with inflammatory bowel disease, those with the NUDT15 mutation had a reduced tolerance for thiopurine dosage over the long term and were more likely to require hospitalization and surgery compared to those without the mutation.

In this study, low dose finasteride or dutasteride treatment was found to reduce prostate specific antigen levels in men with androgenetic alopecia, though levels sometimes remained stable or increased in those with low baseline PSA.

This study concluded that combining systemic cyclosporine A with low-dose corticosteroids effectively treats severe alopecia areata while maintaining safe cyclosporine A levels in the blood.

This review explores the significant impacts of hormonal changes within normal physiological ranges and suggests examining low-dose effects from chemicals disrupting hormonal activity; it presents no new clinical results.

Small hormonal imbalances can cause significant health problems, so more sensitive testing for hormone-disrupting chemicals is needed.

This study found that oral minoxidil was associated with short-term improvements in clinical severity for androgenetic alopecia, whereas oral dutasteride did not show significant early clinical changes in the six-month follow-up.

In this study, researchers aimed to evaluate the safety and tolerability of low-dose oral minoxidil in adolescents, as existing data on its use in this population are limited and there are no specific pediatric guidelines for prescribing it. Results are not reported.

This study found that in healthy young men, oral minoxidil at 5 mg/day led to increased carotid intima-media thickness and vascular aging, suggesting potential cardiovascular side effects at higher doses. A dose-dependent effect was observed, while dutasteride displayed a favorable vascular profile without significant changes.

In this study, low-dose oral minoxidil was found to improve hair density in 80% of pediatric patients with androgenetic alopecia or telogen effluvium, with mild side effects primarily reported.

This review highlights that while low-dose oral minoxidil appears well-tolerated in cancer patients post-chemotherapy, its use during active chemotherapy has shown potential benefits but remains under investigation, with preclinical studies suggesting a protective effect against chemotherapy-induced alopecia.

This retrospective study in a tertiary hair clinic concluded that routine monitoring of heart rate, weight, liver, and kidney function is not necessary for asymptomatic patients with normal baseline values undergoing low-dose oral minoxidil treatment, although monitoring is advised for those with preexisting renal impairment.

This study reviewed adverse events associated with low-dose oral minoxidil for treating alopecia, finding hypertrichosis and fluid retention as common, typically manageable side effects without needing treatment discontinuation.

In this study, low-dose oral minoxidil was found to have a favorable safety profile for treating alopecia, with mostly mild side effects, in both general and hypertensive populations.

This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.

This case report describes successful treatment with low-dose oral minoxidil for endocrine therapy-induced alopecia in a breast cancer patient unresponsive to topical minoxidil.

This study found that high-dose radiation can induce accelerated cellular senescence, inflammation, and loss of epithelial stem cells in mouse and human skin, contributing to radiation dermatitis.

Women treated with X-ray for scalp fungus as children had a higher chance of hair loss, especially with higher radiation doses and severe fungus infections.

This review discusses the role of androgens in women's sexual health and highlights the need for further research on androgen replacement therapy to optimize quality of life, but reports no new clinical results.

The authors concluded that while finasteride 1 mg affects prostate-related pathways, evidence is insufficient to prove clinical benefits for prostate outcomes compared to the established effectiveness of finasteride 5 mg.

This review examines the clinical presentation and management strategies for alopecia areata, focusing on pediatric patients, and highlights the need for addressing its psychological impacts; it reports no new clinical findings.

This study found a complex relationship between cumulative doses of 5-ARIs and all-cause mortality among BPH or AGA patients, with lower doses linked to higher suicide rates and higher doses reducing cardiovascular mortality risk.

In this pilot randomized clinical trial, TRT combined with finasteride increased lean mass, muscle size, and bone mineral density without prostate enlargement in men with spinal cord injury, suggesting potential benefits for body composition and musculoskeletal health.

This prospective study reported that 5 mg daily oral low-dose minoxidil over 24 weeks led to a high prevalence of hypertrichosis in 93% of male androgenetic alopecia patients, particularly affecting younger individuals, but generally had minimal impact on patients’ quality of life.

In this study, 0.2 mg dutasteride significantly improved hair growth in men with androgenetic alopecia compared to placebo over 24 weeks, showing similar efficacy to the higher 0.5 mg dose with a favorable safety profile.

In this retrospective study, researchers found that while combination therapy of spironolactone and oral minoxidil for female alopecia commonly led to mild outpatient-manageable side effects, starting both medications simultaneously reduced hypertrichosis risk, but taking multiple blood pressure medications increased hypotensive symptoms.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.